AbbVie (NYSE:ABBV) Stock Price Down 1.7% – Should You Sell?

AbbVie Inc. (NYSE:ABBV)’s stock price fell 1.7% during trading on Thursday . The stock traded as low as $228.00 and last traded at $232.07. 9,390,226 shares traded hands during trading, an increase of 29% from the average session volume of 7,270,855 shares. The stock had previously closed at $236.19.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 AFFIRM results for risankizumab in moderately‑to‑severe Crohn’s disease boost AbbVie’s immunology growth outlook and support valuation upside as investors reassess long‑term revenue for the drug. Assessing AbbVie (ABBV) Valuation After Positive Phase 3 Crohn’s Disease Trial Results
• Positive Sentiment: AbbVie opened a new Phase 2 study of venetoclax in rare blood cancers (Japan), extending its oncology footprint and adding upside optionality if early signals prove meaningful. AbbVie Advances Venetoclax Into Rare Blood Cancers With New Phase 2 Study
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) highlighted medical weight‑loss adoption and shifting patient demand, supporting the aesthetics revenue runway and diversification of AbbVie’s commercial portfolio. ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA
• Positive Sentiment: Coverage pieces and investor commentary note AbbVie’s strong free‑cash‑flow profile and sizable dividend, which underpin investor confidence despite heavy R&D and M&A activity. (Market commentary)
• Neutral Sentiment: AbbVie completed a large senior‑notes offering (reported at $8B/$7.5B in different releases). The debt sale increases leverage but also provides liquidity for refinancing, buybacks, or acquisitions—a mixed signal for investors. AbbVie Completes $8 Billion Senior Notes Financing Offering
• Neutral Sentiment: Technical/market commentary indicates ABBV is “stabilizing near $233” while testing resistance levels—useful for short‑term traders but not a fundamental catalyst on its own. AbbVie: Stabilizes Near $233 While Testing Resistance
• Neutral Sentiment: AbbVie’s presentation at the TD Cowen healthcare conference provided updated management commentary (transcript available) — more detail for analysts but no single market‑moving surprise. AbbVie Inc. (ABBV) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Negative Sentiment: AbbVie lost a bid to block Tennessee’s 340B law, a legal setback that could pressure pricing/reimbursement dynamics in certain channels and raises policy‑risk concerns for investors focused on drug pricing exposure. AbbVie loses bid to block Tennessee 340B law

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Scotiabank began coverage on AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price on the stock. The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research report on Wednesday, January 28th. Morgan Stanley upped their price target on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Sanford C. Bernstein reissued a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Finally, Royal Bank Of Canada assumed coverage on AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Stock Down 1.7%

The firm has a 50 day moving average of $224.68 and a 200 day moving average of $223.75. The firm has a market cap of $410.34 billion, a PE ratio of 98.33, a P/E/G ratio of 0.81 and a beta of 0.34.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s payout ratio is 293.22%.

Insider Buying and Selling

In related news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.25% of the stock is owned by insiders.

Institutional Investors Weigh In On AbbVie

Large investors have recently added to or reduced their stakes in the company. Storen Legacy Partners LLC purchased a new position in shares of AbbVie during the fourth quarter valued at approximately $247,000. Worthington Financial Partners LLC purchased a new stake in shares of AbbVie in the 4th quarter worth approximately $270,000. Bayban bought a new position in AbbVie during the 4th quarter valued at approximately $845,000. Taylor Securities Services Inc. purchased a new position in AbbVie during the fourth quarter valued at $512,000. Finally, AG Campbell Advisory LLC bought a new stake in AbbVie in the fourth quarter worth $833,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.